Skip to main content
. Author manuscript; available in PMC: 2019 Sep 6.
Published in final edited form as: Clin Cancer Res. 2018 May 30;24(18):4399–4406. doi: 10.1158/1078-0432.CCR-18-0481

Table 3.

Most common (>20%) AEs

All Adverse Event AGS-16M8F(Hyb) N=26 AGS-16C3F(CHO) N=34
Subjects with at least 1 event 26 (100%) 34 (100%)
Fatigue 12 (46.2%) 24 (70.6%)
Nausea 7 (26.9%) 19 (55.9%)
Dry eye 17 (50.0%)
Decreased appetite 15 (44.1%)
Vision blurred 15 (44.1%)
Vomiting 13 (38.2%)
Thrombocytopenia 8 (30.8%) 12 (35.3%)
Headache 11 (32.4%)
Keratitis 11 (32.4%)
Anaemia 10 (29.4%)
Constipation 8 (30.8%) 10 (29.4%)
Dyspnoea 7 (26.9%) 10 (29.4%)
Pyrexia 8 (23.5%)
Epistaxis 7 (20.6%)
Infusion related reaction 7 (20.6%)
Oedema peripheral 7 (20.6%)